2016
Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction
Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, Hill JA, Lee KL, Rouleau JL, Prior DL, Ali IS, Maddury J, Golba KS, White HD, Carson P, Chrzanowski L, Romanov A, Miller AB, Velazquez EJ. Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction. Circulation 2016, 134: 1314-1324. PMID: 27573034, PMCID: PMC5089908, DOI: 10.1161/circulationaha.116.024800.Peer-Reviewed Original ResearchConceptsCoronary artery bypassCause mortalityMedical therapyCardiovascular mortalityYounger patientsEjection fractionHeart failureCABG groupArtery bypassOlder patientsCardiovascular hospitalizationBenefit of CABGEfficacy of CABGCardiopulmonary bypass timeReduced ejection fractionVentricular systolic dysfunctionBaseline ejection fractionCoronary artery diseaseEffect of CABGTen-year outcomesConsistent beneficial effectsMore comorbiditiesSTICH trialBypass timeCardiovascular death
2015
Torsemide Versus Furosemide in Heart Failure Patients
Mentz RJ, Buggey J, Fiuzat M, Ersbøll MK, Schulte PJ, DeVore AD, Eisenstein EL, Anstrom KJ, O'Connor C, Velazquez EJ. Torsemide Versus Furosemide in Heart Failure Patients. Journal Of Cardiovascular Pharmacology 2015, 65: 438-443. PMID: 25945862, PMCID: PMC4423558, DOI: 10.1097/fjc.0000000000000212.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedComorbidityDatabases, FactualFemaleFurosemideHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedNorth CarolinaRetrospective StudiesRisk FactorsSex FactorsSodium Potassium Chloride Symporter InhibitorsSulfonamidesTertiary Care CentersTorsemideTreatment OutcomeUltrasonographyConceptsHeart failure patientsFailure patientsEffects of torsemideFurosemide-treated patientsMore comorbiditiesCause mortalityBaseline characteristicsProspective trialHeart failureLoop diureticsResidual confoundingPatientsDuke HospitalFurosemideRisk adjustmentTorsemideMortalityLab databaseComorbiditiesDiureticsHospitalTrialsSex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Lam CS, McEntegart M, Claggett B, Liu J, Skali H, Lewis E, Køber L, Rouleau J, Velazquez E, Califf R, McMurray JJ, Pfeffer M, Solomon S. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal Of Heart Failure 2015, 17: 301-312. PMID: 25655011, DOI: 10.1002/ejhf.238.Peer-Reviewed Original ResearchConceptsAcute Myocardial Infarction trialMyocardial Infarction trialVentricular systolic dysfunctionHeart failureMyocardial infarctionSystolic dysfunctionClinical characteristicsVentricular volumeKillip class III/IVLeft ventricular systolic dysfunctionRisk of HFClass III/IVHigher long-term riskSmaller left ventricular volumesSimilar ejection fractionLong-term mortalityPost-infarction anginaRisk of hospitalizationSubset of patientsNon-fatal outcomesLong-term riskLeft ventricular volumeAssociation of sexMore comorbiditiesCardiovascular death
2009
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)
Berry C, Pieper KS, White HD, Solomon SD, Van de Werf F, Velazquez EJ, Maggioni AP, Califf RM, Pfeffer MA, McMurray JJ. Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). European Heart Journal 2009, 30: 1450-1456. PMID: 19346225, DOI: 10.1093/eurheartj/ehp102.Peer-Reviewed Original ResearchConceptsPrior CABG patientsCoronary artery bypassMyocardial infarctionCABG patientsPrior CABGHeart failureArtery bypassNon-Q-wave myocardial infarctionPrior coronary artery bypassAcute Myocardial Infarction trialPrimary percutaneous coronary interventionKaplan-Meier ratesSecondary preventive therapyWorse clinical profileMyocardial Infarction trialVentricular systolic dysfunctionHigh-risk patientsPercutaneous coronary interventionAcute myocardial infarctionNumber of patientsNon-fatal outcomesHospital presentationLess aspirinMore comorbiditiesCardiovascular death